Need for Trial Design Change in Epidermal Necrolysis (Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis): Example of Cyclosporine

Affiliations

• ¹ Department of Dermatology, Henri Mondor Hospital, Assitance Publique Hôpitaux de Paris (AP-HP), Créteil, France; Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), Univ Paris Est Créteil, Créteil, France; French National Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France. Electronic address: saskia.oro@aphp.fr.
• ² French National Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France; Medical Intensive Care Unit, Henri Mondor Hospital, Assitance Publique Hôpitaux de Paris (AP-HP), Créteil, France; Université Paris-Est Créteil (UPEC), Créteil, France; Groupe de Recherche Clinique CARMAS, Institut Mondor de Recherche Biomédicale, Université Paris-Est Créteil (UPEC), Créteil, France.
• ³ Department of Dermatology, Henri Mondor Hospital, Assitance Publique Hôpitaux de Paris (AP-HP), Créteil, France; French National Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France; Université Paris-Est Créteil (UPEC), Créteil, France.